Terns Pharmaceuticals Inc. (NASDAQ: TERN), a U.S.-based biotechnology company originally spun out from Eli Lilly’s China R&D center, has unveiled early data for its oral, once-daily glucagon-like peptide-1 receptor (GLP-1R) agonist, TERN-601. The top-line data originates from a Phase I clinical trial, which was a double-blind, placebo-controlled study involving single and multiple ascending doses in healthy adults with obesity or being overweight.
During the 28-day treatment period, with three doses assessed, the maximum placebo-adjusted mean weight loss reached 4.9% at the highest dose of 740mg daily. Notably, 67% of the participants at this top dose experienced a weight loss of 5% or more from their baseline body weight.
When compared to data from other multinational companies developing oral GLP-1R agonists, Terns’ results are competitive. Pfizer’s danuglipron demonstrated a 5.2% weight loss over 28 days in its Phase I trial, while Eli Lilly’s orforglipron achieved a 3.9% weight loss in its respective trial. – Flcube.com
